Swiss ingredients company Lonza Consumer Health and Nutrition is set to invest in its Greenwood, US production facility to expand the production capacity of the site.
Lonza’s Greenwood site produces a variety of empty capsules and finished dosage forms for the biopharma and consumer health and nutrition markets.
The company has not disclosed how much it will spend to upgrade the facility, but claims that the expansion will enhance the company’s production of speciality ingredients.
Approximately 50,000 square feet of manufacturing space will be added as part of the expansion, adding up to 30 jobs at the facility.
According to the company, this expansion forms part of an ongoing investment programme, and the expanded facility is estimated to be fully operational by mid-2019.
Sven Abend, chief operating officer of Lonza Specialty Ingredients said: “This investment further demonstrates our commitment to providing high-quality products and services to our customers worldwide.
“Bringing together expanded manufacturing capabilities for our science-backed ingredients, with the production of our innovative dosage forms in one facility, allows us to offer a broader range of integrated, end-to-end solutions for our customers – from function through to form.”
© FoodBev Media Ltd 2024